1
Country: China | Funding: $370M
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
2
Country: USA | Funding: $96M
Lantern Pharma is creating the AI platform RADR for the development of oncology drugs. It's mainly used to predict the potential response of patients to drugs. RADR uses publicly available databases, commercial clinical research and trial data, proprietary company data derived from ex vivo 3D tumor transcriptome models, genomic data and drug sensitivity data from a wide range of carefully selected sources that are constantly analyzed, tracked and updated. Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors
Lantern Pharma is creating the AI platform RADR for the development of oncology drugs. It's mainly used to predict the potential response of patients to drugs. RADR uses publicly available databases, commercial clinical research and trial data, proprietary company data derived from ex vivo 3D tumor transcriptome models, genomic data and drug sensitivity data from a wide range of carefully selected sources that are constantly analyzed, tracked and updated. Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors
3
Country: USA | Funding: $555.6M
CG Oncology is developing the next evolution of oncolytic immunotherapy for patients with advanced cancers.
CG Oncology is developing the next evolution of oncolytic immunotherapy for patients with advanced cancers.
4
Country: USA | Funding: $209M
Ikena Oncology is a biotechnology company that advances new immunometabolic therapies for cancer.
Ikena Oncology is a biotechnology company that advances new immunometabolic therapies for cancer.
5
Country: USA | Funding: $205M
Flare Therapeutics is a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
Flare Therapeutics is a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
6
Country: USA | Funding: $112.3M
iMDx is focused on cancers with large patient populations and significant unmet need. The company is developing three genetic tests – blood tests for breast cancer and lung cancer, and a urine-based test for bladder cancer.
iMDx is focused on cancers with large patient populations and significant unmet need. The company is developing three genetic tests – blood tests for breast cancer and lung cancer, and a urine-based test for bladder cancer.
7
Country: USA | Funding: $106M
Totus Medicines is a provider of chemical biology technologies by creating life-changing covalent drugs.
Totus Medicines is a provider of chemical biology technologies by creating life-changing covalent drugs.
8
Country: France | Funding: €4.7M
VitaDX is developing a non-invasive medical device for early detection of bladder cancer, based on a syndicate of French academic research.
VitaDX is developing a non-invasive medical device for early detection of bladder cancer, based on a syndicate of French academic research.
9
Country: USA | Funding: $2M
Liquid Biotech is a technology for cancer diagnostics and gene discover
Liquid Biotech is a technology for cancer diagnostics and gene discover
